Biological factors of primary breast cancer tissue and "minimal residual disease";Tumorbiologie des primären mammakarzinoms und der minimalen resterkrankung

Acta Medica Austriaca

Volumn 29, Issue SUPPL. 59, 2002, Pages 27-31

  Schindlbeck, C ^a   Janni, W ^a   Schaffer, P ^a   Shabani, N ^a   Schmitt, M ^b   Harbeck, N ^b   Sommer, H ^a   Braun, S ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Breast cancer; CD 31; CD 44; HER2neu; Minimal residual disease; Topoisomerase II ; Tumor biology

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CD31 ANTIGEN; DNA TOPOISOMERASE (ATP HYDROLYSING); HERMES ANTIGEN; ISOENZYME;

ARTICLE; BONE MARROW; BREAST CANCER; CANCER CYTODIAGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CORRELATION ANALYSIS; DNA REPLICATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MINIMAL RESIDUAL DISEASE; ONCOGENE NEU; PROGNOSIS; PROTEIN EXPRESSION;

BONE MARROW; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM, RESIDUAL;

EID: 0036953824     PISSN: 03038173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL: Monoclonal antibody therapy with edrocolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 1999;5:3999-4004.
2. Braun S, Pantel K: Prognostic significance of micrometastatic bone marrow involvement. Breast Cancer Res Treat 1998;52:201-216.
3. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I-III breast cancer. N Engl J Med 2000;342:525-533.
4. Depowski P, Rosenthal S, Brien T, Stylos S, Johnson R, Ross J: Topoisomerase IIα Expression in Breast Cancer: Correlation with Outcome Variables Mod Pathol 2000;13:542-547.
5. Herrera-Gayol A, Jothy S: Adhesion Proteins in the Biology of Breast Cancer: Contribution of CD 44. Exp Mol Pathol 1999;66:149-156.
6. Leyland-Jones B, Smith I.: Role of Herceptin in Primary Breast Cancer: Views from North America and Europe. Oncology 2001;61:83-91.
7. Morris SF, O'Hanlon D, McLaughlin R, McHale T, Connolly G, Given H: The Prognostic significance of CD 44s and CD 44v6 expression in stage two breast carcinoma: an immunohistochemical study. Eur J Surg Oncol 2001;27:527-531.
8. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G: Differential Expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993;85:1419-1424.
9. Sapino A, Bongiovanni M, Cassoni P, Righi L, Arisio R, Deaglio S, Malavasi F: Expression of CD 31 by cells of extensive ductal in situ and invasive carcinomas of the breast. J Pathol 2001;194:254-261.
10. Schindlbeck C, Janni W, Shabani N, Harbeck N, Bink K, Werner M, Schmitt M, Braun, S: Comparison of the prognostic significance of occult metastatic cells in the bone marrow (OMC-BM) and HER2-status in patients with stage I-III breast cancer (BC). Eur J of Cancer 2001;37:262.
11. Schlimok G, Riethmüller G: Detection, Characterization and tumorigenicity of disseminated tumor cells in human bone marrow. Semin. Cancer Biol 1990;1:207-215.
12. Yarden Y: Biology of HER2 and its Importance in Breast Cancer. Oncology 2001;61:1-13.